Anuh Pharma Limited (ANUHPHR) fundamentals
Anuh Pharma Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ANUHPHR (ISIN INE489G01022). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Anuh Pharma Limited does
Anuh Pharma Limited is engaged in the business of manufacturing and selling bulk drugs and chemicals. The Company's products include active pharmaceutical ingredients and corticosteroids. Its active pharmaceutical ingredients include macrolides, anti-TB, anti-malarial, antibacterial, anti-hypertension, expectorant, quinolones, intermediates and under development. Its macrolides products include erythromycin, erythromycin ethyl succinate, erythromycin stearate, erythromycin estolate, erythromycin propionate, erythromycin phosphate, and others. Its anti-malarial products include sulfadoxine, pyrimethamine, and others. The Company's anti-hypertension products include losartan potassium, telmisartan and atorvastatin calcium. The Company's corticosteroids include anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic, antihistamines and under development. Its anti-inflammatory products include dexamethasone Na phosphate, mometasone furoate and clobetasol butyrate.
Valuation and market data
| Last close | ₹91.70 |
|---|---|
| Market capitalisation | ₹918 crore |
| Enterprise value | ₹912 crore |
| P/E (TTM) | 22.37 |
| Price to book | 2.61 |
| Price to sales (TTM) | 0.68 |
| Book value per share | ₹35.18 |
| Dividend yield | 163.58% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri Dec 20 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹776 crore | ₹54 crore | ₹41 crore | 4.10 |
| Mar 2025 | ₹671 crore | ₹61 crore | ₹47 crore | 9.45 |
| Mar 2024 | ₹659 crore | ₹78 crore | ₹60 crore | 11.98 |
| Mar 2023 | ₹534 crore | ₹47 crore | ₹36 crore | 7.22 |
| Mar 2022 | ₹492 crore | ₹39 crore | ₹31 crore | 6.10 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 71.8% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 28.2% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.